Fresenius SE & Co KGaA (FRE.DE) Stock Price
Fresenius SE & Co KGaA Price
Revenue has compounded at 4.0% per year over the past 19 years to 22.87 B EUR. Earnings per share have grown at 6.2% per year over the last 19 years. Fresenius SE & Co KGaA's net margin stands at 5.5%, broadly stable from 4.9% several years earlier. Fresenius SE & Co KGaA currently offers a dividend yield of about 2.28%. The payout ratio is around 45% of earnings. The dividend has grown at 10.0% per year over the past 19 years. Analysts set a median price target of 57.12 EUR, implying 30.2% above the current price. Of 23 analysts, 21 rate the stock a buy — an overall Buy consensus.
Fresenius SE & Co KGaA stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Fresenius SE & Co KGaA business model & stock analysis
Frequently asked questions about Fresenius SE & Co KGaA
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Analysts currently set an average price target of 56.38 EUR for the Fresenius SE & Co KGaA stock (median: 57.12 EUR), implying +30.6 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Fresenius SE & Co KGaA stock: 21 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Fresenius SE & Co KGaA to generate revenue of 23.76 B EUR and earnings per share of 3.68 EUR.
The Fresenius SE & Co KGaA share (FRE.DE) is listed on 10 stock exchanges, including: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
The expected revenue of Fresenius SE & Co KGaA is 23.76 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Fresenius SE & Co KGaA is 2.07 B EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Fresenius SE & Co KGaA is currently 11.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fresenius SE & Co KGaA stock.
The price-to-sales ratio (P/S) of Fresenius SE & Co KGaA is currently 1.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fresenius SE & Co KGaA stock.
The Eulerpool Quality Score for Fresenius SE & Co KGaA is 3/10.
The ISIN of Fresenius SE & Co KGaA is DE0005785604. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Fresenius SE & Co KGaA is 578560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Fresenius SE & Co KGaA is FRE.DE. The ticker symbol is used to trade Fresenius SE & Co KGaA shares on the stock exchange.
Fresenius SE & Co KGaA stock
Fresenius SE & Co KGaA Peer Group
Fresenius SE & Co KGaA Ticker
Fresenius SE & Co KGaA FIGI
All fundamentals and in-depth analysis of Fresenius SE & Co KGaA
Our stock analysis for Fresenius SE & Co KGaA stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius SE & Co KGaA. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.